Female Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FML037 MIFTS: 53	Female Breast Cancer Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer ¹² ¹⁵

Female Breast Carcinoma ¹² ¹⁵ ⁷³

Malignant Neoplasm of Female Breast ⁷³

Mammary Carcinoma of Female Breast ¹²

Carcinoma of Female Breast ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050671 DOID:7843

NCIt ⁵⁰ C2918

UMLS ⁷³ C0007104 C0235653

Sources

Summaries for Female Breast Cancer

Disease Ontology : ¹² A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to adenoid cystic carcinoma and breast cancer. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are DNA Double-Strand Break Repair and Pathways in cancer. The drugs Epirubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Sources

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)

#	Related Disease	Score	Top Affiliating Genes
1	adenoid cystic carcinoma	29.6	ATM ERBB2 PGR TP53
2	breast cancer	29.5	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
3	in situ carcinoma	29.4	BRCA1 ERBB2 ESR1 PGR TP53
4	endometrial cancer	29.4	AR BRCA1 BRCA2 ERBB2 ESR1 PGR
5	breast carcinoma in situ	29.3	BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
6	female breast nipple and areola cancer	11.1
7	female breast central part cancer	11.1
8	female breast lower-outer quadrant cancer	11.1
9	female breast upper-inner quadrant cancer	11.1
10	female breast lower-inner quadrant cancer	11.1
11	female breast axillary tail cancer	11.1
12	female breast upper-outer quadrant cancer	11.1
13	endometrium carcinoma in situ	10.3	PGR TP53
14	scirrhous adenocarcinoma	10.3	ERBB2 PGR
15	breast apocrine carcinoma	10.3	ERBB2 PGR
16	vestibular gland benign neoplasm	10.3	ESR1 PGR
17	bartholin's gland adenoma	10.3	ESR1 PGR
18	vulvar syringoma	10.3	ESR1 PGR
19	intracystic papillary adenoma	10.3	ERBB2 PGR
20	lung leiomyoma	10.3	ESR1 PGR
21	vulvar benign neoplasm	10.3	ESR1 PGR
22	breast malignant phyllodes tumor	10.3	PGR TP53
23	trigonitis	10.3	ESR1 PGR
24	vulvar leiomyoma	10.3	ESR1 PGR
25	breast metaplastic carcinoma	10.3	ERBB2 PGR
26	progesterone-receptor negative breast cancer	10.2	ERBB2 PGR
27	gastric papillary adenocarcinoma	10.2	ERBB2 TP53
28	predominantly cortical thymoma	10.2	ESR1 PGR
29	olfactory groove meningioma	10.2	PGR TP53
30	bartholin's gland benign neoplasm	10.2	ESR1 PGR
31	pleomorphic adenoma carcinoma	10.2	ERBB2 TP53
32	tracheoesophageal fistula with or without esophageal atresia	10.2	BRCA2 PALB2
33	progesterone resistance	10.2	ESR1 PGR
34	isolated tracheoesophageal fistula	10.2	BRCA2 PALB2
35	cribriform carcinoma	10.2	ESR1 PGR
36	non-proliferative fibrocystic change of the breast	10.2	ERBB2 TP53
37	comedo carcinoma	10.2	ERBB2 ESR1
38	endometrial mucinous adenocarcinoma	10.2	ESR1 PGR
39	adenoid basal cell carcinoma	10.2	ESR1 PGR
40	deep angioma	10.2	ESR1 PGR
41	pancreatic neuroendocrine tumor	10.2	BRCA2 PALB2
42	breast squamous cell carcinoma	10.2	ERBB2 TP53
43	bartholin's duct cyst	10.2	AR TP53
44	estrogen excess	10.2	ESR1 PGR
45	anterior cranial fossa meningioma	10.2	PGR TP53
46	intramuscular hemangioma	10.2	ESR1 PGR
47	hereditary site-specific ovarian cancer syndrome	10.2	BRCA1 BRCA2
48	glioma susceptibility 1	10.2	ERBB2 TP53
49	uterine body mixed cancer	10.2	ERBB2 PGR TP53
50	cervical clear cell adenocarcinoma	10.2	ESR1 PGR

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Breast Fibroadenosis
Deficiency Anemia	Fat Necrosis of Breast
Hypertension, Essential	Hypothyroidism
Mastitis	Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:

Sources

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased homologous recombination repair frequency	GR00151-A-1	10.17	BRCA1
2	Decreased homologous recombination repair frequency	GR00151-A-2	10.17	BRCA1
3	Decreased homologous recombination repair frequency	GR00236-A-1	10.17	BRCA1 BRCA2 PALB2 PGR
4	Decreased homologous recombination repair frequency	GR00236-A-2	10.17	ATM BRCA1 BRCA2 PALB2 PGR
5	Decreased homologous recombination repair frequency	GR00236-A-3	10.17	BRCA1 BRCA2 PALB2
6	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.77	ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
7	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.77	ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
8	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.5	ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
9	Decreased viability after ionizing radiation	GR00232-A-2	9.33	ATM BRCA1 BRCA2
10	Decreased TP53 mRNA expression	GR00389-S-5	9.26	ATM TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

⁴⁶ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.24	AR ATM BRCA1 BRCA2 ERBB2 ERCC4
2	growth/size/body region	MP:0005378	10.22	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
3	behavior/neurological	MP:0005386	10.21	AR ATM BRCA1 BRCA2 ERBB2 ESR1
4	cardiovascular system	MP:0005385	10.2	AR ATM BRCA1 CYP1A1 ERBB2 ESR1
5	homeostasis/metabolism	MP:0005376	10.2	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
6	endocrine/exocrine gland	MP:0005379	10.19	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
7	mortality/aging	MP:0010768	10.18	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
8	embryo	MP:0005380	10.16	AR ATM BRCA1 BRCA2 ERBB2 ESR1
9	integument	MP:0010771	10.13	AR ATM BRCA1 BRCA2 ERBB2 ESR1
10	limbs/digits/tail	MP:0005371	10.01	AR BRCA1 BRCA2 ERBB2 ESR1 PALB2
11	digestive/alimentary	MP:0005381	10	AR BRCA1 BRCA2 ERBB2 ESR1 TP53
12	neoplasm	MP:0002006	9.91	AR ATM BRCA1 BRCA2 ERBB2 ESR1
13	muscle	MP:0005369	9.8	AR BRCA1 ERBB2 ESR1 PGR TP53
14	normal	MP:0002873	9.76	AR BRCA1 BRCA2 CYP1A1 ERBB2 ESR1
15	reproductive system	MP:0005389	9.61	AR ATM BRCA1 BRCA2 ERBB2 ESR1
16	skeleton	MP:0005390	9.17	AR BRCA1 BRCA2 ERBB2 ESR1 PGR

Sources

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Epirubicin

Approved

Phase 4,Phase 3,Phase 1,Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

6055-19-2, 50-18-0

2907

Fluorouracil

Approved

Phase 4,Phase 3

51-21-8

3385

Doxorubicin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

23214-92-8

31703

Methylene blue

Approved, Investigational

Phase 4

61-73-4

Sevoflurane

Approved, Vet_approved

Phase 4,Not Applicable

28523-86-6

5206

Propofol

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

2078-54-8

4943

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 2,Not Applicable

437-38-7

3345

Docetaxel

Approved, Investigational

Phase 4,Phase 3,Phase 2,Early Phase 1

114977-28-5

148124

Letrozole

Approved, Investigational

Phase 4,Phase 3,Phase 2

112809-51-5

3902

Anastrozole

Approved, Investigational

Phase 4,Phase 2

120511-73-1

2187

Toremifene

Approved, Investigational

Phase 4,Phase 3

89778-26-7

3005573

Bupivacaine

Approved, Investigational

Phase 4,Phase 3,Phase 2

2180-92-9, 38396-39-3

2474

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2

1406-16-2

Doxil

Approved June 1999

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

31703

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics, Inhalation

Phase 4,Not Applicable

Anesthetics

Phase 4,Phase 3,Phase 2,Not Applicable

Platelet Aggregation Inhibitors

Phase 4,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Not Applicable

Anesthetics, Intravenous

Phase 4,Phase 2,Not Applicable

Anesthetics, General

Phase 4,Phase 2,Not Applicable

Hypnotics and Sedatives

Phase 4,Phase 3,Phase 2,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Narcotics

Phase 4,Phase 2,Not Applicable

Analgesics

Phase 4,Phase 3,Phase 2,Not Applicable

Adjuvants, Anesthesia

Phase 4,Phase 2,Not Applicable

Analgesics, Opioid

Phase 4,Phase 2,Not Applicable

Antimitotic Agents

Phase 4,Phase 3,Phase 2,Phase 1

Calcium, Dietary

Phase 4,Phase 2,Not Applicable,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Not Applicable

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Estrogen Receptor Antagonists

Phase 4,Phase 3,Phase 2

Steroid Synthesis Inhibitors

Phase 4,Phase 3,Phase 2

Estrogen Antagonists

Phase 4,Phase 3,Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Estrogens

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 4,Phase 3,Phase 2

Aromatase Inhibitors

Phase 4,Phase 3,Phase 2

Anesthetics, Local

Phase 4,Phase 3,Phase 2,Not Applicable

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2,Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1

taxane

Phase 4,Not Applicable

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 183)

#	Name	Status	NCT ID	Phase	Drugs
1	A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging	Unknown status	NCT00531973	Phase 4	liposomal doxorubicin;epirubicin
2	Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients	Unknown status	NCT02982148	Phase 4
3	Anesthesia and Circulating Tumor Cells in Breast Cancer	Completed	NCT02005770	Phase 4	Sevoflurane;Propofol
4	Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer	Recruiting	NCT02089854	Phase 4	Toremifene; Anastrozole
5	PEMF and PEC Blocks in Mastectomy Reconstruction Patients	Recruiting	NCT03360214	Phase 4	Bupivacaine Hydrochloride
6	Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy	Recruiting	NCT03051503	Phase 4	The Transdermal Therapeutic System-Fentanyl (TTS-F)
7	Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia	Recruiting	NCT03812003	Phase 4	Remifentanil
8	Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide	Active, not recruiting	NCT02502864	Phase 4	Standard of Care: Docetaxel;Standard of Care: Cyclophosphamide
9	HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer	Not yet recruiting	NCT03111615	Phase 4	Aromatase Inhibitors
10	Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn	Withdrawn	NCT03007381	Phase 4	Ketorolac Tromethamine;Normal Saline
11	Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)	Unknown status	NCT01583426	Phase 3	nab-Paclitaxel;Paclitaxel
12	Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.	Completed	NCT03381417	Phase 3	pegcyte;Neulastim
13	Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer	Completed	NCT02980965	Phase 3	letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
14	A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer	Completed	NCT03403712	Phase 3	fosnetupitant/ palonosetron;netupitant/palonosetron;dexamethasone
15	Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer	Completed	NCT01426880	Phase 2, Phase 3	Carboplatin;background treatment
16	A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)	Completed	NCT02125344	Phase 3	non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
17	Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life	Recruiting	NCT03585218	Phase 3
18	Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer	Recruiting	NCT03351062	Phase 3	Tamoxifen;Toremifene
19	Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients	Recruiting	NCT03525990	Phase 3
20	Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate	Recruiting	NCT02600923	Phase 3	Palbociclib;Letrozole
21	Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block	Not yet recruiting	NCT03063073	Phase 3	Dexmedetomidine Injection [Precedex];Bupivacaine
22	Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients	Not yet recruiting	NCT03686215	Phase 3
23	Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients	Unknown status	NCT01168505	Phase 2	ferric hydroxide saccharate
24	Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction	Completed	NCT01466270	Phase 2	donepezil hydrochloride;Placebo
25	Treatment for Patients Suffering From Anemia Due to Chemotherapy	Completed	NCT00120692	Phase 2	Darbepoetin Alfa;Recombinant Human Erythropoietin
26	Dose Dense TC + Pegfilgrastim Support for Breast Cancer	Completed	NCT01671319	Phase 2	docetaxel + cyclophosphamide + pegfilgrastim
27	Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients	Completed	NCT01204125	Phase 2	paclitaxel;Iniparib (SAR2405550 -BSI-201)
28	Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy	Completed	NCT01091974	Phase 2	armodafinil;Placebo Comparator
29	Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy	Completed	NCT02527746	Phase 1, Phase 2	EC regimen
30	The HEALS Project - Health Education and Active Living for Surviving Seniors	Completed	NCT01305044	Phase 2
31	Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor	Recruiting	NCT03518138	Phase 2	Q-122;Placebo
32	Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications	Recruiting	NCT03518242	Phase 2	Cyclophosphamide;Methotrexate;Capecitabine
33	Immunogenicity and Safety of DCs in Breast Cancer	Recruiting	NCT03450044	Phase 1, Phase 2
34	Tissue Stresses of Cancer (Force Horizon 2020)	Recruiting	NCT03238144	Phase 1, Phase 2
35	Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)	Recruiting	NCT03065621	Phase 2	Palbociclib
36	Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer	Recruiting	NCT02942355	Phase 2	anastrozole;Palbociclib
37	Study on Androgen Receptor and Triple Negative Breast Cancer	Recruiting	NCT03383679	Phase 2	Darolutamide;Capecitabine
38	Combination Study of SV-BR-1-GM in Combination With Pembrolizumab	Recruiting	NCT03328026	Phase 1, Phase 2	Low dose cyclophosphamide
39	Effect of Methylphenidate on Cancer-related Cognitive Impairment	Recruiting	NCT02970500	Phase 2	Methylphenidate HCl 10Mg SR;Placebo Group
40	A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant	Recruiting	NCT02540330	Phase 2	Fulvestrant
41	Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients	Recruiting	NCT03342417	Phase 2
42	PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery	Recruiting	NCT03084536	Phase 2	Bupivacaine;Gabapentin;Celecoxib;Acetaminophen;Midazolam;Fentanyl
43	Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer	Recruiting	NCT03112590	Phase 1, Phase 2	Paclitaxel;Trastuzumab
44	Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery	Recruiting	NCT03113825	Phase 2	AVB-620
45	Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer	Recruiting	NCT03384914	Phase 2
46	Denosumab as an add-on Neoadjuvant Treatment (GeparX)	Recruiting	NCT02682693	Phase 2	Denosumab;nab-Paclitaxel;Epirubicin;Cyclophosphamide;Carboplatin;Trastuzumab;Pertuzumab
47	Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer	Recruiting	NCT03250676	Phase 1, Phase 2	H3B-6545
48	Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1	Recruiting	NCT03630809	Phase 2
49	Phase II Trial for Large ER-Negative Breast Cancers	Active, not recruiting	NCT01869192	Phase 2	Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
50	Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer	Active, not recruiting	NCT01203839	Phase 2

Search NIH Clinical Center for Female Breast Cancer

Sources

Genetic Tests for Female Breast Cancer

Sources

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

⁴¹

Breast, Lymph Node, Bone, Prostate, Lung, Heart, Cortex

Sources

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 447)

#	Title	Authors	Year
1	Acceptability and satisfaction of Project MOVE: a pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors. ( 29409128 )	Pullen T....Caperchione C.M.	2018
2	Natural Terpenoids Against Female Breast Cancer: a 5-year Recent Research. ( 29446727 )	Ateba S.B....Njamen D.	2018
3	Survival Comparisons Between Early Male and Female Breast Cancer Patients. ( 29891971 )	Wang K....Li H.Y.	2018
4	Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. ( 29098396 )	Eggemann H....Ignatov A.	2018
5	Improving Visualization of Female Breast Cancer Survival Estimates: Analysis Using Interactive Mapping Reports. ( 29724710 )	Ben Ramadan A.A....Schmaltz C.L.	2018
6	Ambient air emissions of polycyclic aromatic hydrocarbons and female breast cancer incidence in US. ( 29730800 )	Stults W.P....Wei Y.	2018
7	Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting. ( 29280294 )	Wen D....Shan B.	2018
8	Personality risk factors of occurrence of female breast cancer: a case-control study in China. ( 29699414 )	Dong X.Y....Jin J.	2018
9	Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. ( 29678178 )		2018
10	Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29294225 )		2018
11	Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. ( 29396493 )		2018
12	Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. ( 29804200 )		2018
13	Health-related quality of life of African-American female breast cancer survivors, survivors of other cancers, and those without cancer. ( 29704078 )		2018
14	Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study. ( 29624915 )		2018
15	Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. ( 29673111 )		2018
16	Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis. ( 29478945 )		2018
17	A Comparison Between Upper Arm and Chest for Optimal Site of Totally Implanted Venous Access Ports in Patients with Female Breast Cancer. ( 29481918 )		2018
18	Work and Female Breast Cancer: The State of the Evidence, 2002-2017. ( 29658425 )		2018
19	Breast specific functional and symptom analysis in female breast cancer survivors. ( 29893309 )		2018
20	Influence of social conditions on the quality of life of female breast cancer survivors. ( 30557918 )	Oliveira NPD...Souza DLB	2018
21	Is there an association between liraglutide use and female breast cancer in a real-world setting? ( 30538516 )	Funch D...Dore DD	2018
22	Trends in incidence and mortality of female breast cancer during transition in Central China. ( 30538571 )	Cheng Y...Nie S	2018
23	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. ( 30519815 )	Manson QF...van Diest PJ	2018
24	Expression of chemerin correlates with a poor prognosis in female breast cancer patients. ( 30498371 )	El-Sagheer G...Mohamed M	2018
25	Second primary cancer after female breast cancer: Familial risks and cause of death. ( 30479046 )	Zheng G...Hemminki K	2018
26	Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. ( 29660599 )	Lim IL...Taib NAM	2018
27	Hypermethylated LATS2 gene with decreased expression in female breast cancer: A case control study from North India. ( 30010037 )	Sadaf...Husain SA	2018
28	Factors Associated with Functional Decline in Elderly Female Breast Cancer Patients in Appalachia. ( 30027004 )	Singh R...Tirona MT	2018
29	Prevention of Acute Radiation-Induced Skin Reaction with NPE® Camellia Sinensis Nonfermentatum Extract in Female Breast Cancer Patients Undergoing Postoperative Radiotherapy: A Single Centre, Prospective, Open-Label Pilot Study. ( 30057821 )	N?f G...Zwahlen DR	2018
30	Evaluation of the delivery of survivorship care plans for South Asian female breast cancer survivors residing in Canada. ( 30111971 )	Singh-Carlson S...Oshan G	2018
31	Occupational variation in the risk of female breast cancer in the Nordic countries. ( 30151565 )	Katuwal S...Pukkala E	2018
32	Male breast cancer: a disease distinct from female breast cancer. ( 30267249 )	Gucalp A...Cardoso F	2018
33	Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. ( 30297439 )	Matthews A...Bhaskaran K	2018
34	Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. ( 30371238 )	Nowsheen S...Herrmann J	2018
35	Prognostic Influence of Preoperative Mammographic Breast Density in Operable Invasive Female Breast Cancer. ( 30375450 )	Hwang KT...Oh B	2018
36	DDT exposure in early childhood and female breast cancer: Evidence from an ecological study in Taiwan. ( 30376997 )	Chang S...Tang MC	2018
37	Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project. ( 28223083 )	Nakamura K....Tamakoshi A.	2017
38	Estimated and Interactively Visualized Female Breast Cancer Incidence Rates in Missouri Senate Districts: 2008-2012. ( 29403576 )	Ben Ramadan A.A....Schmaltz C.L.	2017
39	BRIP1/FANCJ Mutation Analysis in a Family with History of Male and Female Breast Cancer in India. ( 28382101 )	Venkateshwari A....Palle K.	2017
40	No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations. ( 28490891 )	Semlali A....Alanazi M.S.	2017
41	Metastasis and its Related Factors in Female Breast Cancer Patients in Kerman, Iran ( 28669169 )	Kalantari Khandani B....Khanjani N.	2017
42	[The coping styles and its relationship with quality of life among 1 968 female breast cancer patients in Shanghai in 2014]. ( 28763916 )	Deng Q.L....Yu J.M.	2017
43	Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients. ( 29135103 )	Panousis D....Xepapadakis G.	2017
44	Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study. ( 28732040 )	Donnelly T.T....Singh R.	2017
45	Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. ( 28607590 )	Xu T....He B.S.	2017
46	Province Disparity on Female Breast Cancer in Iran. ( 29259957 )	Ayubi E....Khazaei S.	2017
47	Physical symptoms and working performance in female breast cancer survivors: a systematic review. ( 28325132 )	Zomkowski K....Sperandio F.F.	2017
48	Marital adjustment in the context of female breast cancer: A systematic review. ( 28342270 )	BrandALo T....Matos P.M.	2017
49	Model-based Recursive Partitioning for Survival of Iranian Female Breast Cancer Patients: Comparing with Parametric Survival Models. ( 28451527 )	Safe M....Mahjub H.	2017
50	Exploring neighborhood inequality in female breast cancer incidence in Tehran using Bayesian spatial models and a spatial scan statistic. ( 28774168 )	Ayubi E....Yazdani K.	2017

Sources

Genes for Female Breast Cancer

Genes related to Female Breast Cancer (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PGR	Progesterone Receptor	Protein Coding	28.88	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	28.58	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR1	Estrogen Receptor 1	Protein Coding	27.28	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
4	TOP2A	DNA Topoisomerase II Alpha	Protein Coding	24.11	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
5	BRCA2	BRCA2, DNA Repair Associated	Protein Coding	23.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	PALB2	Partner And Localizer Of BRCA2	Protein Coding	21.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	TP53	Tumor Protein P53	Protein Coding	21.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	AR	Androgen Receptor	Protein Coding	21.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	TOX3	TOX High Mobility Group Box Family Member 3	Protein Coding	20.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	20.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	BRCA1	BRCA1, DNA Repair Associated	Protein Coding	20.65	DISEASES inferred ¹⁵ ¹⁵
12	PHB	Prohibitin	Protein Coding	20.38	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	ATM	ATM Serine/Threonine Kinase	Protein Coding	20.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	ERCC4	ERCC Excision Repair 4, Endonuclease Catalytic Subunit	Protein Coding	20.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Female Breast Cancer

Sources

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Sources

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 27)

#	Super pathways	Score	Top Affiliating Genes
1	DNA Double-Strand Break Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B-Cdk1 complex ⁶⁶ DNA damage_DNA-damage-induced responses ²² DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Homology Directed Repair ⁶⁶ Non-homologous end joining ¹ Non-homologous end-joining ³⁷ Processing of DNA double-strand break ends ⁶⁶	13.07	ATM BRCA1 BRCA2 ERCC4 PALB2 TP53
2	Pathways in cancer ³⁷	12.7	AR BRCA2 ERBB2 ESR1 TP53
3	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.58	ATM BRCA1 BRCA2 ERBB2 ESR1 TP53
4	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.55	BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
5	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.45	ATM BRCA1 BRCA2 ERCC4 ESR1 TP53
6	MicroRNAs in cancer ³⁷	12.39	ATM BRCA1 ERBB2 TP53
7	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) ⁶⁶ Show member pathways Homologous recombination ³⁷ Homologous recombination ¹ Resolution of D-Loop Structures ⁶⁶ Resolution of D-loop Structures through Holliday Junction Intermediates ⁶⁶	12.02	ATM BRCA1 BRCA2 PALB2
8	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways ATR Signaling ¹ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.02	ATM BRCA1 BRCA2 ERCC4 PALB2
9	DNA Damage ⁴	11.97	ATM BRCA1 BRCA2 ERCC4 PHB TOP2A
10	DNA Damage Response (only ATM dependent) ¹	11.86	ATM ERBB2 TP53
11	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.83	ERBB2 ESR1 PGR
12	Fanconi anemia pathway ³⁷ ⁶⁶	11.77	BRCA1 BRCA2 ERCC4 PALB2
13	Nuclear Receptor transcription pathway ⁶⁶ Show member pathways Nuclear Receptors ¹	11.74	AR ESR1 PGR
14	ATM Pathway ⁶⁴ Show member pathways ATM Signaling Pathway ¹	11.71	ATM BRCA1 TP53
15	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.68	ATM BRCA1 BRCA2 TP53
16	DNA damage_Role of Brca1 and Brca2 in DNA repair ²²	11.48	ATM BRCA1 BRCA2 TP53
17	Platinum drug resistance ³⁷	11.42	ATM BRCA1 ERBB2 TOP2A TP53
18	FOXA1 transcription factor network ¹ Show member pathways FOXA transcription factor networks ¹	11.41	AR BRCA1 ESR1
19	Integrated Cancer Pathway ¹	11.4	ATM BRCA1 TP53
20	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.38	ATM BRCA1 ERBB2 TP53
21	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.37	ATM BRCA1 TP53
22	Integrated Breast Cancer Pathway ¹	11.35	AR ATM BRCA1 BRCA2 ESR1 PHB
23	GADD45 Pathway ⁶⁴	11.21	ATM BRCA1 TP53
24	BARD1 signaling events ¹	11.15	ATM BRCA1 TP53
25	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.98	ATM TP53
26	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	10.93	ATM BRCA1 TP53
27	Estrogen Receptor Pathway ¹	10.73	CYP1A1 ESR1

Sources

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	9.77	AR ATM BRCA1 BRCA2 ERBB2 ERCC4
2	protein-containing complex	GO:0032991	9.63	AR BRCA1 BRCA2 ESR1 TOP2A TP53
3	nuclear chromosome, telomeric region	GO:0000784	9.5	ATM BRCA2 ERCC4
4	nucleoplasm	GO:0005654	9.36	AR ATM BRCA1 BRCA2 ERCC4 ESR1
5	lateral element	GO:0000800	9.26	BRCA1 BRCA2
6	cytoplasm	GO:0005737	10.11	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 28)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	9.95	AR ATM BRCA1 ESR1 PGR TOP2A
2	cell proliferation	GO:0008283	9.88	AR BRCA2 CYP1A1 ERBB2 TP53
3	protein deubiquitination	GO:0016579	9.87	AR BRCA1 ESR1 TP53
4	DNA repair	GO:0006281	9.83	ATM BRCA1 BRCA2 ERCC4 PALB2
5	positive regulation of gene expression	GO:0010628	9.8	AR ATM BRCA1 ERBB2 PHB TP53
6	DNA recombination	GO:0006310	9.79	BRCA1 BRCA2 PALB2
7	multicellular organism growth	GO:0035264	9.75	AR BRCA2 PALB2
8	double-strand break repair via nonhomologous end joining	GO:0006303	9.72	ATM BRCA1 ERCC4
9	steroid hormone mediated signaling pathway	GO:0043401	9.71	AR ESR1 PGR
10	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.7	ATM BRCA1 BRCA2
11	positive regulation of transcription, DNA-templated	GO:0045893	9.7	AR BRCA1 BRCA2 ESR1 PHB TOX3
12	nucleotide-excision repair	GO:0006289	9.67	BRCA2 ERCC4 TP53
13	double-strand break repair via homologous recombination	GO:0000724	9.67	BRCA1 BRCA2 ERCC4 PALB2
14	response to immobilization stress	GO:0035902	9.64	CYP1A1 PHB
15	resolution of meiotic recombination intermediates	GO:0000712	9.63	ERCC4 TOP2A
16	mammary gland alveolus development	GO:0060749	9.63	AR ESR1
17	DNA double-strand break processing	GO:0000729	9.62	ATM BRCA1
18	replicative senescence	GO:0090399	9.61	ATM TP53
19	inner cell mass cell proliferation	GO:0001833	9.61	BRCA2 PALB2
20	negative regulation of telomerase activity	GO:0051974	9.6	ERCC4 TP53
21	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.59	ESR1 TP53
22	positive regulation of transcription by RNA polymerase III	GO:0045945	9.58	AR ERBB2
23	progesterone receptor signaling pathway	GO:0050847	9.56	PGR PHB
24	chordate embryonic development	GO:0043009	9.51	BRCA1 BRCA2
25	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.46	AR PGR
26	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.43	BRCA1 BRCA2 TP53
27	regulation of apoptotic process	GO:0042981	9.43	ATM BRCA1 ESR1 PHB TOX3 TP53
28	cellular response to DNA damage stimulus	GO:0006974	9.17	ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	zinc ion binding	GO:0008270	9.96	AR BRCA1 ESR1 PGR TP53
2	identical protein binding	GO:0042802	9.87	BRCA1 BRCA2 ERBB2 ERCC4 ESR1 PGR
3	chromatin binding	GO:0003682	9.83	AR ESR1 TOP2A TOX3 TP53
4	transcription regulatory region DNA binding	GO:0044212	9.8	AR BRCA1 PHB TP53
5	histone deacetylase binding	GO:0042826	9.72	PHB TOP2A TP53
6	protein N-terminus binding	GO:0047485	9.71	ATM ERCC4 TP53
7	DNA binding	GO:0003677	9.7	AR ATM BRCA1 BRCA2 ERCC4 ESR1
8	ATPase binding	GO:0051117	9.69	AR ESR1 PGR
9	steroid hormone receptor activity	GO:0003707	9.65	AR ESR1 PGR
10	nuclear receptor activity	GO:0004879	9.58	AR ESR1 PGR
11	protein C-terminus binding	GO:0008022	9.55	BRCA2 ERBB2 ERCC4 PHB TOP2A
12	TFIID-class transcription factor complex binding	GO:0001094	9.52	ERCC4 TP53
13	estrogen response element binding	GO:0034056	9.46	ESR1 TOX3
14	steroid binding	GO:0005496	9.43	AR ESR1 PGR
15	enzyme binding	GO:0019899	9.23	AR BRCA1 CYP1A1 ESR1 PGR PHB
16	protein binding	GO:0005515	10.21	AR ATM BRCA1 BRCA2 CYP1A1 ERBB2

Sources

Sources for Female Breast Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia